

Target	
Mechanism of Action	<ul style="list-style-type: none"> • Skeleton I: Capsid Binding Inhibitor • Skeleton II: RNA replication Inhibitor
Indication - Primary	<ul style="list-style-type: none"> • Anti-rhinovirals for common cold • Antivirals against exacerbations of COPD and Asthma
Indication - Expansion	<ul style="list-style-type: none"> • Broad antiviral activity against EV68, EV71, PV
Route of Administration	<ul style="list-style-type: none"> • PO preferred
Competitive Advantage	<ul style="list-style-type: none"> • No drugs available against rhinovirus as well as enterovirus/poliovirus
Data Files	<ul style="list-style-type: none"> • Medicinal Chemistry approach : under SAR study • Anti-viral activity data by cell based assay <ul style="list-style-type: none"> - Skeleton I (KR-25865): HRV14 0.053μM, HRV21 0.08μM, HRV71 0.016μM, PV3 0.046μM - Skeleton II (KR-26106): HRV14 0.39μM, HRV21 1.8μM, HRV71 0.8μM
IP Status	<ul style="list-style-type: none"> • Novel structures
Collaboration Model	<ul style="list-style-type: none"> • Collaborative research
Contact (Science)	<ul style="list-style-type: none"> • Young Sik Jung, Ph.D.(ysjung@kRICT.re.kr, +82-42-860-7135)
Contact (Licensing)	<ul style="list-style-type: none"> • Moon Geun Jung (Technology marketing office, mgjung@kRICT.re.kr, +82-42-860-7746) • Choon-gil Kim (Technology marketing office, joykim@kRICT.re.kr, +82-42-860-7079) • Kyung Sun Choi (Technology marketing office, chanian@kRICT.re.kr, +82-42-860-7076)